Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;17(1):131-8.
doi: 10.1007/s12192-011-0294-2. Epub 2011 Oct 21.

Heat shock protein expression in canine osteosarcoma

Affiliations

Heat shock protein expression in canine osteosarcoma

Mariarita Romanucci et al. Cell Stress Chaperones. 2012 Jan.

Abstract

Abnormal levels of heat shock proteins have been observed in a number of human neoplasms and demonstrate prognostic, predictive and therapeutic implications. Since osteosarcoma (OSA) in dogs provides an important model for the same disease in humans, the aim of this study was to evaluate the immunohistochemical expression of Hsp27, Hsp72, Hsp73 and Hsp90 in 18 samples of canine appendicular OSA, in relation to histological grade and overall survival (OS), in order to investigate their potential prognostic, predictive and/or therapeutic value. A semiquantitative method was used for the analysis of the results. Hsp27, Hsp73 and Hsp90 showed a variably intense, cytoplasmic and nuclear immunoreactivity that was not associated with histological type or grade. On the other hand, a high percentage of Hsp72 immunostaining was significantly associated with grade III (P < 0.01) and a lack of immunolabelling was significantly correlated to a longer OS (P = 0.006). Neoplastic emboli were occasionally positive for Hsp27, faintly immunoreactive for Hsp72 and intensely immunolabelled by Hsp73 and Hsp90. In conclusion, absence of Hsp72 immunosignal appears to be associated with a favourable prognosis whilst the widespread Hsp90 immunoreactivity detected in all tumour cases as well as in neoplastic emboli, suggests this protein could be targeted in the therapy of canine OSA, and likewise in its human counterpart.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Fibroblastic osteosarcoma: moderate Hsp27 immunoreactivity with diffuse cytoplasmic and scattered nuclear localization (bar = 10 μm). Inset intense and diffuse positivity in the cytoplasm of multinucleated giant cells (bar = 30 μm)
Fig. 2
Fig. 2
Nonproductive osteoblastic osteosarcoma: intense Hsp72 immunosignal predominantly located in the nucleus of tumour cells (bar = 10 μm). Inset absence of immunolabelling in a lymphatic embolus (bar = 60 μm)
Fig. 3
Fig. 3
Productive osteoblastic osteosarcoma: intense, diffuse, cytoplasmic and nuclear Hsp73 immunoreactivity (bar = 22 μm). Inset scattered, strong nuclear positivities associated with low cytoplasmic immunosignal in a multinucleated giant cell (bar = 30 μm)
Fig. 4
Fig. 4
Productive osteoblastic osteosarcoma: intense and diffuse cytoplasmic Hsp90 immunolabelling in primary tumour cells as well as in a lymphatic embolus (inset) (bar = 22 μm; inset bar = 60 μm)
Fig. 5
Fig. 5
The figure shows the percentage of expression of each Hsp (absent, low, moderate, high) in the different histological grades of canine osteosarcoma. Hsp27, Hsp73 and Hsp90 expression did not appear to be related to histological grade whereas high percentage of Hsp72 immunostaining was significantly associated with high-grade (grade III) osteosarcoma (P = 0.009)
Fig. 6
Fig. 6
Kaplan–Meier plots showing influence on survival of Hsp72 immunoexpression: a Absence of Hsp72 immunodetection appeared to be significantly associated to a longer post-surgical OS (P = 0.006); bc Hsp72 expression scores did not show a significant relation to OS (P = 0.058–P = 0.112)

Similar articles

Cited by

References

    1. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer. 2005;113:179–188. doi: 10.1002/ijc.20611. - DOI - PubMed
    1. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007;15:1783–1788. doi: 10.1158/1078-0432.CCR-06-1892. - DOI - PubMed
    1. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc. 1995;206:1555–1560. - PubMed
    1. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31:164–172. doi: 10.1016/j.tibs.2006.01.006. - DOI - PubMed
    1. Cardoso F, Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferriera F, Paesmans M, Piccart M. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral lymph nodes. Ann Oncol. 2001;12:615–620. doi: 10.1023/A:1011182524684. - DOI - PubMed

Publication types

Substances